


Package Leaflet: Information for the User
Solifenacin/Tamsulosin Stadafarma 6 mg/0.4 mg Modified Release Tablets EFG
solifenacin, succinate/tamsulosin, hydrochloride
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the pack
Solifenacin/tamsulosin is a combination of two different medicines called solifenacin and tamsulosin in one tablet. Solifenacin belongs to a group of medicines called anticholinergics and tamsulosin belongs to a group of medicines called alpha-blockers.
Solifenacin/tamsulosin is used in men to treat both moderate to severe filling symptoms and emptying symptoms of the lower urinary tract caused by bladder problems and by an enlarged prostate (benign prostatic hyperplasia). Solifenacin/tamsulosin is used when previous monotherapy treatment for this condition did not sufficiently relieve the symptoms.
When the prostate gland enlarges, it can cause urinary problems (emptying symptoms) such as delayed urination (difficulty starting urination), reduced urine flow (weak stream), dripping, and a feeling of incomplete emptying of the bladder. At the same time, the bladder is also affected and contracts spontaneously at times when urination is not desired. This causes filling symptoms such as changes in bladder sensation, urgency (having a strong and sudden need to urinate without prior notice), and having to urinate more frequently.
Solifenacin reduces the involuntary contractions of the bladder and increases the amount of urine that your bladder can hold. Therefore, you can expect to wait longer before you need to go to the bathroom. Tamsulosin allows urine to pass more easily through the urethra and facilitates urination.
Do not take Solifenacin/Tamsulosin Stadafarma if:
Tell your doctor if you think you have any of these conditions.
Warnings and precautions
Consult your doctor or pharmacist before starting Solifenacin/Tamsulosin Stadafarma if:
Regular medical check-ups are necessary to monitor the development of the condition for which you are being treated.
Solifenacin/tamsulosin may affect blood pressure, which can cause dizziness, drowsiness, or rarely, fainting (orthostatic hypotension). You should sit or lie down if you experience any of these symptoms until they have disappeared.
If you are going to undergo or have scheduled eye surgery due to cataracts or increased pressure in the eyes (glaucoma), please inform your ophthalmologist that you have previously used, are using, or plan to use solifenacin/tamsulosin. The specialist can then take the necessary precautions regarding medication and surgical techniques to be used. Ask your doctor if you should postpone or temporarily interrupt taking this medicine when you are going to undergo eye surgery for cataracts or increased pressure in the eyes (glaucoma).
Children and adolescents
Do not give this medicine to children and adolescents.
Using Solifenacin/Tamsulosin Stadafarma with other medicines
Tell your doctor or pharmacist if you are using, have recently used, or might use any other medicines.
It is especially important that you inform your doctor if you are using:
Using Solifenacin/Tamsulosin Stadafarma with food and drinks
Solifenacin/tamsulosin can be taken with or without food, according to your preferences.
Pregnancy, breastfeeding, and fertility
Solifenacin/tamsulosin is not indicated for use in women.
In men, abnormal ejaculation (ejaculation disorder) has been reported. This means that semen is not released through the urethra, but instead goes into the bladder (retrograde ejaculation) or that the ejaculated volume is reduced or nonexistent (ejaculatory failure). This phenomenon is harmless.
Driving and using machines
Solifenacin/tamsulosin may cause dizziness, blurred vision, fatigue, and less frequently, drowsiness. If you experience these side effects, do not drive or use machines.
Solifenacin/Tamsulosin Stadafarma contains sodium
This medicine contains less than 23 mg of sodium (1 mmol) per tablet; this is essentially "sodium-free".
Follow exactly the administration instructions of this medicine given by your doctor or pharmacist. In case of doubt, consult your doctor or pharmacist again.
The maximum daily dose is one tablet containing 6 mg of solifenacin and 0.4 mg of tamsulosin, taken orally. It can be taken with or without food, depending on your preferences. Do not crush or chew the tablet.
If you take more Solifenacin/Tamsulosin Stadafarma than you should
If you have taken more tablets than you were told to, or if someone else has taken your tablets by mistake, contact your doctor, pharmacist, or hospital immediately for advice.
In case of overdose, your doctor may treat you with activated charcoal; emergency stomach lavage may be useful if performed within one hour of overdose. Do not induce vomiting.
The symptoms of overdose may include: dry mouth, dizziness, and blurred vision, seeing things that are not there (hallucinations), over-excitability, convulsions, difficulty breathing, increased heart rate (tachycardia), inability to empty the bladder completely or partially or to urinate (urinary retention), and/or undesirable increase in blood pressure.
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service. Phone: 91 562 04 20, indicating the medicine and the amount ingested.
If you forget to take Solifenacin/Tamsulosin Stadafarma
Take your next Solifenacin/Tamsulosin tablet as normal. Do not take a double dose to make up for forgotten doses.
If you stop taking Solifenacin/Tamsulosin Stadafarma
If you stop taking solifenacin/tamsulosin, your initial symptoms may reappear or worsen. Always consult your doctor if you are considering stopping treatment.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
The most serious side effect that has been observed with a frequency of less than 1 in 100 men during treatment with solifenacin/tamsulosin in clinical studies is acute urinary retention, which is a sudden inability to urinate. If you think you may have this, go to your doctor immediately. You may need to stop taking solifenacin/tamsulosin.
Solifenacin/tamsulosin may cause allergic reactions:
If you experience an allergic reaction or a severe skin reaction (e.g. formation of blisters and peeling of the skin), you should inform your doctor immediately and stop using solifenacin/tamsulosin. Treatment and/or measures should be applied.
Common side effects (may affect up to 1 in 10 men)
Uncommon side effects (may affect up to 1 in 100 men)
Rare side effects (may affect up to 1 in 1,000 men)
Very rare side effects (may affect up to 1 in 10,000 men)
Frequency not known (cannot be estimated from the available data)
Reporting of side effects
If you experience any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Spanish Medicines Agency's website: www.notificaRAM.es. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton and blister after "EXP". The expiry date is the last day of the month stated.
Do not store above 25°C.
Medicines should not be disposed of via wastewater or household waste. Return any unused medicine to your pharmacist. Ask your pharmacist how to dispose of medicines no longer required. This will help to protect the environment.
Composition of Solifenacin/Tamsulosin Stadafarma
Appearance of the product and pack contents
Solifenacin/Tamsulosin Stadafarma 6 mg/0.4 mg tablets are round, biconvex, film-coated, red, and marked with "T7S" on one side.
Solifenacin/Tamsulosin Stadafarma is available in blisters containing 10, 14, 20, 28, 30, 50, 56, 60, 90, 100, or 200 modified-release tablets or unit-dose blisters containing 10x1, 14x1, 20x1, 28x1, 30x1, 50x1, 56x1, 60x1, 90x1, 100x1, or 200x1 modified-release tablets.
Not all pack sizes may be marketed.
Marketing authorisation holder and manufacturer
Marketing authorisation holder
Laboratorio STADA, S.L.
Frederic Mompou, 5
08960 Sant Just Desvern (Barcelona)
Spain
Manufacturer
Synthon Hispania S.L.,
C/ Castelló, nº1,
Sant Boi de Llobregat,
08830 Barcelona, Spain
or
Synthon BV,
Microweg 22,
6545 CM Nijmegen,
Netherlands
or
Synthon s.r.o.,
Brnenská 32/cp. 597,
678 01 Blansko,
Czech Republic
or
STADA Arzneimittel AG
Stadastrasse 2 – 18
61118 Bad Vilbel
Germany
Date of last revision of this leaflet:April 2023
Detailed information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/
The average price of SOLIFENACIN/TAMSULOSIN STADAPHARMA 6 mg/0.4 mg MODIFIED-RELEASE TABLETS in November, 2025 is around 30.07 EUR. Prices may vary depending on the region, pharmacy, and whether a prescription is required. Always check with a local pharmacy or online source for the most accurate information.
The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for SOLIFENACIN/TAMSULOSIN STADAPHARMA 6 mg/0.4 mg MODIFIED-RELEASE TABLETS – subject to medical assessment and local rules.